Search Results
Aug 26, 2026, 07:25 ET Secondo la nuova classifica del 2026 di Drinks International, Michter's è il whiskey più apprezzato al mondo
numero uno dei whiskey più apprezzati al mondo per quattro anni consecutivi va oltre tutto ciò che avrei mai potuto immaginare. È un onore per il quale io e tutti i miei colleghi qui nello stabilimento siamo straordinariamente grati."Oltre alla sua distilleria principale nella zona Shively di Louisville,
More news about: Michter's Distillery
Aug 25, 2026, 09:15 ET /C O R R E C T I O N -- Akeso, Inc./
potential ADC of choice in both mono or combination therapies.Akeso is advancing its IO2.0 + ADC2.0 strategy, built on proprietary bispecific and multispecific antibody technology and centered on cornerstone IO2.0 assets including ivonescimab and cadonilimab. Through this approach, the company is elevating
More news about: Akeso, Inc.
Aug 25, 2026, 06:15 ET Innovent Announces 2026 Interim Results and Business Updates
Next-gen IO cornerstone, potential TAM over US$40 billion for first wave of indications, global co-development with TakedaA global multi-regional Phase 3 study (MarsLight-11) in IO-resistant squamous non-small cell lung cancer (NSCLC) is ongoing, and with expansion into IO-resistant
More news about: Innovent Biologics
Aug 24, 2026, 08:46 ET Timekettle Expands AI Ecosystem with Babel OS 3.0, Powering Real-Time Translation on RayNeo iO Smart Glasses
hardware.Babel OS 3.0 Powers Real-Time Translation on RayNeo iOBabel OS 3.0 is Timekettle's proprietary AI translation platform developed for natural, real-time cross-language communication.On RayNeo iO, Babel OS 3.0 powers the device's Live Translation feature,
More news about: Shenzhen Timekettle Technologies Co., Ltd.
Aug 23, 2026, 21:00 ET Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
ATG-125 (B7-H3 x PD-L1 bispecific ADC): ATG-125 is an "IO + ADC" dual-function molecule targeting B7-H3 and PD-L1, integrating the direct cytotoxic activity of an ADC with the durable immune activation of IO therapies. By simultaneously blocking B7-H3- and PD-L1-mediated immunosuppressive
More news about: Antengene Corporation Limited
Aug 22, 2026, 11:35 ET RayNeo erweitert sein AR-Sortiment für Endverbraucher: Vorstellung der RayNeo iO Smart-Brillen und der kinotauglichen RayNeo GT-Serie
und Weise zugeschnitten sind, wie Menschen täglich arbeiten und sich entspannen." RayNeo iO Smart-Brillen: Ganztägige Ambient Intelligence & Produktivität Die RayNeo iO Smart-Brillen wurden für Fachleute, Führungskräfte und Nutzer mehrerer Bildschirme entwickelt und verbinden
More news about: RayNeo
Aug 22, 2026, 11:32 ET RayNeo élargit sa gamme de produits de réalité augmentée grand public : présentation des lunettes connectées RayNeo iO et de la série RayNeo GT cinématographique
au quotidien. »Lunettes connectées RayNeo iO : Intelligence ambiante et productivité au quotidienConçues pour les professionnels, les cadres et les personnes qui utilisent plusieurs écrans, les lunettes connectées RayNeo iO allient le style rétro des Crown Panto à un environnement
More news about: RayNeo
Aug 21, 2026, 08:58 ET Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation, and Accelerating Progress Towards C-MNC
increase. The company's differentiated innovation pipeline continues to expand, and it has now established multiple technology platforms—next-generation IO, Hanjugator ADC, multi-specific T-cell engager (TCE), and AI—with more than 50 early-stage pipeline molecules in reserve, covering therapeutic areas including
More news about: Henlius
Aug 21, 2026, 03:00 ET RayNeo Expands Consumer AR Lineup: Unveiling RayNeo iO Smart Glasses and Cinematic RayNeo GT Series
2026."RayNeo iO and the GT Series represent a fundamental commitment to purpose-built spatial hardware," said Howie Li, Founder and CEO of RayNeo. "Rather than compromising with a single device that tries to do everything, we designed two dedicated experiences: the iO as an invisible, all-day
More news about: RayNeo
Aug 21, 2026, 03:00 ET RayNeo Expands Consumer AR Lineup: Unveiling RayNeo iO Smart Glasses and Cinematic RayNeo GT Series
2026."RayNeo iO and the GT Series represent a fundamental commitment to purpose-built spatial hardware," said Howie Li, Founder and CEO of RayNeo. "Rather than compromising with a single device that tries to do everything, we designed two dedicated experiences: the iO as an invisible, all-day
More news about: RayNeo
Aug 21, 2026, 03:00 ET RayNeo amplía su gama de realidad aumentada para el consumidor
diario". Gafas inteligentes RayNeo iO: Inteligencia ambiental y productividad durante todo el díaDiseñadas para profesionales, ejecutivos y usuarios de múltiples pantallas, las gafas inteligentes RayNeo iO combinan el estilo retro de Crown Panto con información
More news about: RayNeo
Aug 18, 2026, 09:00 ET PM360 Announces 2026 Trailblazer Award Finalists
Omnichannel & Communications, ApnimedManaged Markets/Payer Strategies: Nianwei (Nina) Qiu, U.S. Oncology Market Access Strategy Lead, IO-GI, AstraZenecaManaged Markets/Payer Strategies: Niu (Amy) Niu, Director, Market Access Marketing, Sumitomo Pharma America, Inc.Men's
More news about: PM360
Aug 18, 2026, 08:18 ET GrubMarket Expands into the UK with the Acquisition of Fresh Produce Leader, JR Holland
agentic enterprise AI assistants that empower food supply chain businesses with deep insights, intelligent analyses, and workflow automation; Orders IO, GrubMarket's custom-branded mobile and online ordering eCommerce solution; and GrubPay, the company's digital payments platform specifically designed
More news about: GrubMarket
Aug 17, 2026, 07:18 ET Kelun-Biotech Announces 2026 Interim Results
components, as well as the pairing with a diverse range of targeting conjugates including antibodies, small molecules, and peptides that leverage TAA/IO/ anti-angiogenetic-based mechanisms, the Company has proactively positioned innovative DC assets, including single-payload DCs such as radioisotope-based/
More news about: Kelun-biotech
Aug 14, 2026, 10:00 ET Phanes Therapeutics Receives FDA Fast Track Designation for Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
Phanes' anti-CLDN18.2/CD47 bispecific antibody that functions as an innate immunity enhancer (I2E), an emerging class of immuno-oncology (IO) agents. Spevatamig is currently in Phase 2 studies for the treatment of multiple forms of gastrointestinal cancers.This designation
More news about: Phanes Therapeutics, Inc.
Aug 13, 2026, 12:02 ET Pilot Project Between BioCytics and LIDE Biotech
manufacturing capabilities with LIDE's unique, patient-derived xenograft technologies (PDX, miniPDX®, and IO-based PDX models) to streamline the development of immuno-oncology (IO) treatments.
More news about: BioCytics Inc.
Aug 12, 2026, 08:17 ET Ivonescimab Plus Chemotherapy Approved for First-Line Squamous NSCLC; HARMONi-6 Establishes New Gold Standard in Lung Cancer Treatment
standard of care for squamous NSCLC, and established a new benchmark for clinical benefit.Currently, ivonescimab stands as the cornerstone of Akeso's IO2.0 + ADC2.0 strategy. We are advancing a portfolio of highly differentiated therapies that continue to elevate and reshape the global treatment landscape
More news about: Akeso, Inc.
Aug 10, 2026, 00:05 ET Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
bispecific antibody), for the treatment of advanced breast cancer. This study aims to explore the potential of Akeso's "IO2.0 + ADC2.0" regimen in advanced breast cancer, with a particular focus on first-line treatment of HR+/HER2- breast cancer and triple-negative
More news about: Akeso, Inc.
Aug 05, 2026, 20:00 ET Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China
forward for investigational next-generation immuno-oncology (IO) therapies in overcoming colorectal cancer—a classic 'immune-cold' tumor. Previously initiated studies of IBI363 include a pivotal Phase 2 clinical study (NCT07217301) in China for IO-naïve melanoma (acral and mucosal subtypes). A global, multi-center,
More news about: Innovent Biologics
Aug 04, 2026, 09:00 ET PM360 Announces 2026 Lifetime Achievement Award Honoree, CMO of the Year, and Brand Champions
Omnichannel & Communications, ApnimedManaged Markets/Payer StrategiesNianwei (Nina) Qiu, U.S. Oncology Market Access Strategy Lead, IO-GI, AstraZenecaManaged Markets/Payer StrategiesNiu (Amy) Niu, Director, Market Access Marketing, Sumitomo Pharma America, Inc.Men's
More news about: PM360
Jul 29, 2026, 08:55 ET Encore AI Raises $30M to Deploy the Only Enterprise AI Platform Built to Generate Revenue from Customer Interactions
Insait IO rebrands as Encore AI and raises $30M Series A to deploy AI agents powered by the company's patented Interaction Mining technology across every channelNEW YORK, July 29, 2026 /PRNewswire/
More news about: Encore AI
Jul 27, 2026, 22:35 ET Akeso IO2.0 + ADC2.0 Strategy Makes Another Advancement: First Patient Dosed in Phase Ib/II Study of HER3 ADC (AK138D1) Combined with Ivonescimab in Lung Cancer
ivonescimab (PD-1/VEGF bispecific antibody) for advanced non-small cell lung cancer (NSCLC). The study aims to evaluate the potential of Akeso's IO2.0 + ADC2.0 regimen across multiple settings in advanced NSCLC, including: first-line treatment, treatment after EGFR-TKI resistance, and treatment after
More news about: Akeso, Inc.
Jul 27, 2026, 07:30 ET Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565
featuring high-value targets, differentiated designs, and global potential. Building on this foundation, the Company continues to advance its "ADC + IO" strategy—on one hand by actively exploring high-quality combination regimens, including multiple ongoing clinical studies evaluating ADCs in combination
More news about: Kelun-Biotech
Jul 27, 2026, 07:24 ET 首個雙載荷ADC進入臨床，科倫博泰SKB565獲臨床試驗批准通知書
全性，其突出的腫瘤治療潛力為後續臨床開發提供了有力支撐。憑藉在ADC領域的技術沉澱與平臺優勢，科倫博泰已佈局一系列結合高價值靶點、差異化設計並具備全球潛力的創新分子。在此基礎上，公司進一步拓展「ADC+IO」策略——一方面聚焦優質聯用療法的探索，包括正在開展臨床的多種ADC與PD-(L)1單抗聯合方案，以及PD-1/VEGF雙抗SKB118與公司眾多專有ADC資產的聯用；另一方面推進一體化策略研發，在單一ADC分子中整合具有協同作用機制功能元件。科倫博泰首席執行官葛均友博士表示：「SKB565是我們『A
More news about: 科倫博泰
Jul 23, 2026, 08:47 ET Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8013, an Antibody Drug Conjugate Targeting CD25 for the Treatment of Advanced Solid Tumors
developing several additional ADCs targeting Folate Receptor alpha, Trop2 and Her2 along with additional innovative oncology assets directed at important IO targets, including novel bispecific targeting PD-L1/4-1BB and PD1/IL15, all in early-stage clinical studies.About Bio-Thera SolutionsBio-Thera
More news about: Bio-Thera Solutions, Ltd